The $400,000 SBIR Phase I award will support the further development of Tiba’s targeted delivery platform for a range of inflammatory lung diseases.
Tiba Biotech Announces Strategic Collaboration with CVIM to Advance RNA-Based Livestock Vaccines
April 9, 2026
Tiba announces strategic collaboration with Pirbright’s CVIM to accelerate the development of next-generation RNA vaccines targeting high-impact livestock diseases using the RNABL™ delivery platform.
Tiba Biotech Receives NCI Grant to Advance Next-Generation RNA Cancer Immunotherapies
September 25, 2025
The $400,000 SBIR Phase I award will support development of Tiba’s tissue-targeted delivery platform and proprietary enhanced self-amplifying RNA payloads.
Tiba announced the results of a challenge study evaluating the efficacy of a novel vaccine for Foot and Mouth Disease (FMD) in cattle using Tiba’s RNABL™ delivery platform.
Tiba announces a BARDA FASTx award to develop an RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein using Tiba’s novel RNABL™ delivery platform
The government of NSW (Australia) is investing in a range of animal disease vaccines with leading institutions and technology providers, including Tiba Biotech. A pilot project intended to fast-track an mRNA vaccine for border disease virus (BDV) has been successfully manufactured for the first time in NSW.
NIH awards Tiba a Phase II SBIR grant to advance RNA vaccines against pandemic influenza
September 5, 2023
Tiba Biotech receives an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
CEPI Partners with Tiba Biotech to Evaluate Next-Generation RNA Vaccine Platform Technology to Respond to ‘Disease X’
January 12, 2023
As the first award to be granted under CEPI’s innovation program, CEPI will provide US$2 million to advance Tiba Biotech’s novel RNA nanoparticle delivery platform, RNABL™.
Tiba Biotech announces the extension of an earlier CIVICs initiative with scientists from the University of Minnesota and Emory University to study the level and duration of protection of Tiba’s next-generation RNA vaccines.
Tiba Biotech and the Australian State of New South Wales Enter Partnership to Address Emergency Animal Disease Threats
September 27, 2022
Tiba Biotech, a preclinical biopharmaceutical company, today announced it has entered into a five-year, multi-million US dollar agreement with the Australian state government of New South Wales (NSW) to develop next-generation mRNA vaccines against emergency animal diseases that threaten Australia’s livestock industry and domestic food security.
Keep connected with us
© 2026 Tiba Biotech LLC. All rights reserved